Trial Profile
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fosbretabulin (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Sponsors Mateon Therapeutics; OXiGENE
- 12 Apr 2014 New trial record